IO Biotech Announces Acceptance of Abstracts to be Presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting
IO Biotech (IOBT) announced the acceptance of two abstracts for presentation at the 2025 AACR Annual Meeting in Chicago. The presentations will showcase new non-clinical data for their cancer vaccine candidates:
1. Data demonstrating how IO102-IO103, their lead candidate currently in Phase 3 trials for advanced melanoma, controls tumor growth through target-specific T-cell activation.
2. Preclinical data for IO170, their pipeline candidate targeting TGF-beta, showing promising antitumor activity.
Additionally, Dr. Mads Hald Andersen, the company's scientific co-founder, will chair and speak at an educational session on cancer vaccines, exploring the latest advances in cancer vaccine research.
IO Biotech (IOBT) ha annunciato l'accettazione di due abstract per la presentazione al 2025 AACR Annual Meeting a Chicago. Le presentazioni metteranno in mostra nuovi dati non clinici per i loro candidati vaccini contro il cancro:
1. Dati che dimostrano come IO102-IO103, il loro candidato principale attualmente in fase 3 di sperimentazione per melanoma avanzato, controlli la crescita tumorale attraverso l'attivazione specifica delle cellule T.
2. Dati preclinici per IO170, il loro candidato in pipeline mirato al TGF-beta, che mostrano un'attività antitumorale promettente.
Inoltre, il Dr. Mads Hald Andersen, co-fondatore scientifico dell'azienda, presiederà e interverrà a una sessione educativa sui vaccini contro il cancro, esplorando gli ultimi progressi nella ricerca sui vaccini contro il cancro.
IO Biotech (IOBT) anunció la aceptación de dos resúmenes para su presentación en el 2025 AACR Annual Meeting en Chicago. Las presentaciones mostrarán nuevos datos no clínicos sobre sus candidatos a vacunas contra el cáncer:
1. Datos que demuestran cómo IO102-IO103, su candidato principal actualmente en ensayos de fase 3 para melanoma avanzado, controla el crecimiento tumoral a través de la activación específica de células T.
2. Datos preclínicos para IO170, su candidato en desarrollo que apunta a TGF-beta, mostrando una prometedora actividad antitumoral.
Además, el Dr. Mads Hald Andersen, cofundador científico de la empresa, presidirá y hablará en una sesión educativa sobre vacunas contra el cáncer, explorando los últimos avances en la investigación de vacunas contra el cáncer.
IO Biotech (IOBT)는 2025 AACR Annual Meeting에서 발표할 두 개의 초록이 수락되었다고 발표했습니다. 발표에서는 그들의 암 백신 후보에 대한 새로운 비임상 데이터를 선보일 예정입니다:
1. 현재 진행 중인 3상 시험에서 진행성 흑색종을 위한 주요 후보인 IO102-IO103가 표적 특이적 T세포 활성화를 통해 종양 성장을 어떻게 조절하는지를 보여주는 데이터.
2. TGF-beta를 표적으로 하는 파이프라인 후보인 IO170의 전임상 데이터로, 유망한 항종양 활성을 보여줍니다.
추가로, 회사의 과학 공동 창립자인 Mads Hald Andersen 박사가 암 백신에 대한 교육 세션을 주재하고 연설하며, 암 백신 연구의 최신 발전을 탐구할 예정입니다.
IO Biotech (IOBT) a annoncé l'acceptation de deux résumés pour une présentation lors de la 2025 AACR Annual Meeting à Chicago. Les présentations mettront en avant de nouvelles données non cliniques sur leurs candidats vaccins contre le cancer :
1. Des données montrant comment IO102-IO103, leur candidat principal actuellement en phase 3 d'essai pour le mélanome avancé, contrôle la croissance tumorale grâce à l'activation spécifique des cellules T.
2. Des données précliniques pour IO170, leur candidat en développement ciblant le TGF-bêta, montrant une activité antitumorale prometteuse.
De plus, le Dr Mads Hald Andersen, cofondateur scientifique de l'entreprise, animera et interviendra lors d'une session éducative sur les vaccins contre le cancer, explorant les dernières avancées dans la recherche sur les vaccins contre le cancer.
IO Biotech (IOBT) gab die Annahme von zwei Abstracts für die Präsentation auf dem 2025 AACR Annual Meeting in Chicago bekannt. Die Präsentationen werden neue nicht-klinische Daten zu ihren Krebsimpfstoffkandidaten vorstellen:
1. Daten, die zeigen, wie IO102-IO103, ihr Hauptkandidat, der sich derzeit in Phase-3-Studien für fortgeschrittenes Melanom befindet, das Tumorwachstum durch zielgerichtete Aktivierung von T-Zellen kontrolliert.
2. Präklinische Daten für IO170, ihren Pipeline-Kandidaten, der auf TGF-beta abzielt und vielversprechende antitumorale Aktivitäten zeigt.
Darüber hinaus wird Dr. Mads Hald Andersen, der wissenschaftliche Mitbegründer des Unternehmens, eine Bildungssitzung über Krebsimpfstoffe leiten und sprechen, in der die neuesten Fortschritte in der Krebsimpfstoffforschung erkundet werden.
- Lead candidate IO102-IO103 advancing in Phase 3 trial for advanced melanoma
- Promising preclinical data for pipeline candidate IO170 showing antitumor activity
- None.
• New non-clinical data strengthens evidence of contributions of IO102 and IO103 to tumor growth control through target specific T-cell activation, offering a distinct and complementary approach to checkpoint inhibitors
• New preclinical data for IO170 add to growing body of evidence supporting the potential of immune-modulatory therapeutic cancer vaccines to treat a wide range of cancers
NEW YORK, March 25, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced that two abstracts have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025 taking place April 25-30 in Chicago, Illinois. One of the posters will share insights, using non-clinical models, related to IO Biotech’s lead investigational candidate, IO102-IO103, currently being evaluated in a pivotal Phase 3 trial in advanced melanoma. The second poster contains new preclinical data for the third candidate in the company’s pipeline, IO170, which targets transforming growth factor beta (TGF-beta). Additionally, Mads Hald Andersen, DMSc, PhD, Director of the Center for Cancer Immune Therapy (CCIT) and scientific co-founder of IO Biotech, will be chairing and speaking at an education session on cancer vaccines.
“We are pleased to share new data at AACR that expand our understanding of the underlying mechanism of action of our lead candidate, IO102-IO103, currently being investigated in a pivotal Phase 3 trial,” said Ayako Wakatsuki Pedersen, PhD, Senior Vice President of Translational Research at IO Biotech. “We are also excited to share that we have seen promising activity for an additional candidate being studied in our pipeline, IO170. Together, the data from both of these non-clinical studies further solidify the potential of our proprietary T-win immune-modulatory cancer vaccine platform.”
Dr. Pedersen continued, “We also look forward to the educational session on cancer vaccines, chaired by our scientific founder, that will explore the latest advances in cancer vaccine research and the distinct mechanisms of action of different approaches and their potential to reshape cancer immunotherapy.”
Presentation Details
Title: Immune-modulatory therapeutic cancer vaccines against IDO1 and PD-L1 control tumor growth through target specific changes in the tumor microenvironment
Abstract Number: 2241
Date and Time: Monday, April 28, 2025, 9:00 AM – 12:00 PM CT
Location: Poster Section 38
Poster Board Number: 12
Presenter: Marion Chapellier, PhD
Title: A TGFβ-directed immune-modulatory vaccine induces T cell activation and drives antitumor activity by modulating the tumor microenvironment
Abstract Number: 2257
Date and Time: Monday, April 28, 2025, 9:00 AM – 12:00 PM CT
Location: Poster Section 38
Poster Board Number: 28
Presenter: Justin Joseph, PhD
Education Session: Immune Modulatory Vaccines
This session will explore the latest advancements in cancer vaccine research, spanning from preclinical innovation to clinical translation.
Session: ED59. Cancer Vaccines 101
Date and Time: Saturday, April 26, 2025, 12:30 – 2:00 pm CT
Session format and speakers:
- Dr. Smita Nair (30 min, including discussion)
- Dr. Kristen Radford (30 min, including discussion)
- Dr. Mads Hald Andersen (30 min, including discussion)
About IO Biotech
IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines based on its T-win® platform. The T-win platform is based on a novel approach to cancer vaccines designed to activate T cells to target both tumor cells and the immune-suppressive cells in the tumor microenvironment. IO Biotech is advancing its lead investigational cancer vaccine candidate, Cylembio® (imsapepimut and etimupepimut, adjuvanted) also known as IO102-IO103 in clinical trials, and additional pipeline candidates through preclinical development. Based on positive Phase 1/2 first line metastatic melanoma data, IO102-IO103, in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), has been granted a Breakthrough Therapy Designation for the treatment of advanced melanoma by the US Food and Drug Administration. IO Biotech is headquartered in Copenhagen, Denmark and has US headquarters in New York, New York.
For further information, please visit www.iobiotech.com. Follow us on our social media channels on LinkedIn and X (@IOBiotech).
Cylembio is a trademark of IO Biotech ApS.
Forward-Looking Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including regarding the timing or outcome of primary analysis of the company’s Phase 3 trial, other current or future clinical trials, their progress, enrollment or results, or the company’s financial position or cash runway, are based on IO Biotech’s current assumptions and expectations of future events and trends, which affect or may affect its business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Except to the extent required by law, IO Biotech undertakes no obligation to update these statements, whether as a result of any new information, future developments or otherwise.
Contact:
Investors
Maryann Cimino, Director of Investor Relations
IO Biotech, Inc.
617-710-7305
mci@iobiotech.com
Media
Julie Funesti
Edelman
917-498-1967
julie.funesti@edelman.com
FAQ
What are the key findings for IO Biotech's (IOBT) IO102-IO103 cancer vaccine presented at AACR 2025?
What stage is IO Biotech's (IOBT) lead candidate IO102-IO103 currently in?
What are the preliminary results for IO Biotech's (IOBT) IO170 cancer vaccine candidate?
When and where will IO Biotech (IOBT) present their cancer vaccine data in 2025?
